Goods & Services

Pharmaceutical preparations; pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations.

Abstract

A therapeutic agent for a T cell malignancy includes a bispecific antigen-binding molecule including (1) at least one portion that specifically binds to a target tumor antigen expressed on T cell tumor cells, and (2) at least one portion that specifically binds to a normal T cell-side target antigen having subtypes, provided that the target tumor antigen expressed on the T cell tumor cells is either not present on normal T cells, or if present, the normal T cells are not substantially activated when the bispecific antigen-binding molecule binds to the same antigen as the target tumor antigen present on the normal T cells, but binding of the bispecific antigen-binding molecule to the normal T cell-side target antigen activates the normal T cells, and a sufficient proportion of a subtype of the normal T cell-side target antigen is present to provide a sufficient number of activated T cells for the treatment.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The problem addressed by the present invention is to produce a novel antibody recognizing a mutant CALR protein at a site distinct from the sites recognized by conventional antibodies, and to provide pharmaceuticals using the same. The present invention provides a composition for treating a tumor, the composition comprising an antibody or an antigen-binding fragment thereof that binds to a region N-terminal to a mutation site in a mutant calreticulin and binds to the mutant calreticulin present on the cell surface. The present invention also provides a method for producing an antibody that binds to a region N-terminal to a mutation site in a mutant calreticulin, said method comprising a step for screening: an antibody that binds to the mutant calreticulin present on a cell surface; or an antibody that binds to a dimer of the mutant calreticulin.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12P 21/08 - Monoclonal antibodies

Abstract

Provided are: a novel compound which is useful for the treatment of diseases to be prevented, ameliorated, and/or treated by suppressing axon degeneration; and a pharmaceutical composition containing the same.　The present invention pertains to: a compound represented by general formula (I) [in the formula, R1, R2, R3, X1, X2, X3, X4, X5, Y1, Y2, Z1, and a ring C are as described in the specification and the claims] or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C12N 9/99 - Enzyme inactivation by chemical treatment

Abstract

The present invention provides a design method for a light source of a light irradiation device that is used during usage or storage of a photosensitive substance or when managing a patient who has been administered a photosensitive substance. A design method according to the present invention comprises: a step for obtaining an emission spectrum of a reference light source; a step for obtaining an emission spectrum of a light source to be evaluated; a step for obtaining an absorption coefficient of a photosensitive substance; and a step for using the absorption coefficient and the obtained light source spectra to find the ratio of absorption energy in the photosensitive substance caused by irradiation from the reference light source to absorption energy in the photosensitive substance caused by irradiation from the light source to be evaluated, and using said ratio to design a light source.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the prevention of cardiovascular disease; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of tumours; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for use in oncology; diagnostic preparations for medical purposes; diagnostic reagents for medical purposes for use in detecting cardiovascular disease; diagnostic reagents for medical purposes for use in detecting tumours.

Abstract

The present invention addresses the problem of providing a novel treatment method for T-cell tumors that can induce cell damage in tumor cells and can be used in the treatment of a T-cell tumor of a subject with T-cell dysfunction. The present invention provides a therapeutic agent for a T-cell tumor of a subject with T-cell dysfunction, said therapeutic agent comprising a bispecific antigen-binding molecule, wherein the bispecific antigen-binding molecule includes (1) at least one section that specifically binds to a target tumor antigen expressed in T-cell tumor cells, and (2) at least one section that specifically binds to an antigen which is a normal T-cell-side target antigen and has a subtype, provided that the target tumor antigen expressed in T-cell tumor cells is not present in normal T-cells, or if present, the normal T-cells are substantially not activated when the bispecific antigen-binding molecule binds to the antigen that is present in the normal T-cells and is the same as the target tumor antigen, and a sufficient ratio of the subtype of the normal T-cell-side target antigen is present such that the normal T-cells are activated by the bispecific antigen-binding molecule binding to the normal T-cell-side target antigen and a sufficient number of activated T-cells for treatment of the T-cell tumor are provided.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins

Abstract

The present invention addresses the problem of providing a new tumor treatment method that is capable of inducing cytotoxicity to tumor cells and is unlikely to cause immunodeficiency and cytokine release syndrome. The present invention provides a therapeutic agent for tumors (tumors excluding T-cell tumors), the therapeutic agent comprising a bispecific antigen-binding molecule. The bispecific antigen-binding molecule includes (1) at least one portion that specifically binds to a target tumor antigen expressed by tumor cells, and (2) at least one portion that specifically binds to a normal T-cell-side target antigen having subtypes. The target tumor antigen expressed by the tumor cells is not present in normal T-cells. Even if the target tumor antigen is present in normal T-cells, the normal T-cells are substantially not activated when the bispecific antigen-binding molecule binds to the same antigen as the target tumor antigen present in the normal T-cells. The normal T-cells are activated by having the bispecific antigen-binding molecule bind to the normal T-cell-side target antigen. In order to provide a sufficient number of activated T-cells for the treatment of a tumor, the subtypes of the normal T-cell-side target antigen are present at sufficient proportions.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/46 - Hybrid immunoglobulins

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations.

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations.

Abstract

A pharmaceutical which exhibits sufficient anticancer effects by using an antibody which binds to a mutant CALR protein and another anticancer agent in combination. A pharmaceutical for preventing and/or treating a cancer, including an antibody which specifically binds to a mutant calreticulin protein or a functional fragment thereof and a drug selected from the group consisting of an alkylating agent, a platinum preparation, an antimetabolite, a ribonucleotide reductase inhibitor, a nucleotide analog, a topoisomerase inhibitor, a microtubule polymerization inhibitor, an antitumor antibiotic, an interferon, a cytokine preparation, a molecular targeting drug, a nucleic acid synthesis inhibitor, a jak inhibitor, and a cancer immunotherapeutic agent in combination.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 38/21 - Interferons
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are: a novel compound that is useful for the treatment of diseases to be prevented, ameliorated, and/or treated by suppressing axon degeneration; and a pharmaceutical composition containing the same.　The present invention relates to: a compound represented by general formula (I) [in the formula, Ra, Rb, X1, R1, L1, L2, and R2 are as disclosed in the specification and as set forth in the claims] or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same.

IPC Classes  ?

• C07D 213/55 - AcidsEsters
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 38/05 - Dipeptides
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 213/56 - Amides
• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• C07D 213/82 - AmidesImides in position 3
• C07D 401/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/12 - Genes encoding animal proteins

Abstract

The present invention provides a pharmaceutical composition containing an antibody or a functional fragment thereof capable of binding to a mutant CALR to exhibit a therapeutic effect.　The present invention relates to a bispecific antibody or a functional fragment thereof having a first domain that specifically binds to an epitope of a mutant CALR protein and a second domain that specifically binds to a CD3 antigen, wherein: a CDR in the first domain has (a) an amino acid sequence having 80% or higher homology with amino acid sequences represented by SEQ ID NO: 6 (VHCDR1), SEQ ID NO: 7 (VHCDR2), and SEQ ID NO: 8 (VHCDR3), and an amino acid sequence having 80% or higher homology with amino acid sequences represented by SEQ ID NO: 9 (VLCDR1), SEQ ID NO: 10 (VLCDR2) and SEQ ID NO: 11 (VLCDR3); and a CDR in the second domain has an amino acid sequence having 80% or higher homology with an amino acid sequence represented by SEQ ID NO: 12 (VHCDR1), SEQ ID NO: 13 (VHCDR2) or SEQ ID NO: 14 (VHCDR3), and an amino acid sequence having 80% or higher homology with an amino acid sequence represented by SEQ ID NO: 15 (VLCDR2), SEQ ID NO:16 (VLCDR2) or SEQ ID NO: 17 (VLCDR3).

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A crystalline form I of a compound represented by Formula (VII-1): A crystalline form I of a compound represented by Formula (VII-1): A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 Å in the powder X-ray diffraction pattern.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Goods & Services

crackers

Abstract

Conditions necessary for antibodies to human PD-1 to have agonist activity are searched and an optimized agonist antibody is provided based on the conditions and used as a therapeutic for human inflammatory diseases. An agonist antibody to human PD-1 or a functional fragment thereof, wherein the antibody or a functional fragment thereof binds to domain #7 of human PD-1 as shown in SEQ ID NO: 9 is provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A method for producing a compound represented by formula (1): A method for producing a compound represented by formula (1): A method for producing a compound represented by formula (1): or a salt thereof, comprising: a step B of producing a compound represented by formula (3): A method for producing a compound represented by formula (1): or a salt thereof, comprising: a step B of producing a compound represented by formula (3): A method for producing a compound represented by formula (1): or a salt thereof, comprising: a step B of producing a compound represented by formula (3): [in the formula (3), Boc represents a tert-butoxycarbonyl group] or a salt thereof by using a compound represented by formula (2): A method for producing a compound represented by formula (1): or a salt thereof, comprising: a step B of producing a compound represented by formula (3): [in the formula (3), Boc represents a tert-butoxycarbonyl group] or a salt thereof by using a compound represented by formula (2): A method for producing a compound represented by formula (1): or a salt thereof, comprising: a step B of producing a compound represented by formula (3): [in the formula (3), Boc represents a tert-butoxycarbonyl group] or a salt thereof by using a compound represented by formula (2): [in the formula (2), Ra represents a hydrogen atom or an optionally substituted arylmethyl group, Rb represents an optionally substituted alkyl or cyclic alkyl group, R3 represents a hydrogen atom, a halogen atom, or a thiazol-2-yl group, and Xa represents a hydrogen atom or a halogen atom] or a salt thereof; and a step C of producing the compound represented by the formula (1) or the salt thereof by using the compound represented by the formula (3) or the salt thereof.

IPC Classes  ?

• C07D 487/08 - Bridged systems

Abstract

A compound represented by general formula (I): [in formula (I), n represents an integer of 0 to 2; X represents CH, CF, CCl, N, CHCH=N, CHCH=CH, or CHCH=CF; Y represents O, NH, or a single bond; Z represents a hydroxy group or an oxo group; R1represents a hydrogen atom, a C1 to C6 alkyl group, a three- to six-membered cycloalkyl group, a four- to eight-membered heterocycloalkyl group, a six- to ten-membered aryl group, a five- to ten-membered heteroaryl group, a C2 to C6 alkenyl group, a C2 to C6 alkynyl group, a group represented by -CO-R2, a group represented by -COO-R2, a group represented by -CONH-R2, or a group represented by -B(OR4)OR5, and these groups may be substituted; R2, R4, and R5 each represent a hydrogen atom, alkyl group, etc.] or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 31/14 - Antivirals for RNA viruses
• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations.

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations.

Abstract

The present invention addresses the problem of providing a novel method for treating T cell tumor, whereby it becomes possible to induce the cell damage of a tumor cell and which is less likely to cause immunodeficiency.　According to the present invention, a T cell tumor therapeutic agent comprising a bispecific antigen-binding molecule is provided, in which the bispecific antigen-binding molecule includes (1) at least one segment capable of binding specifically to a target tumor antigen expressed in a T cell tumor cell and (2) at least one segment capable of binding specifically to a normal T cell-side target antigen having a subtype. The target tumor antigen expressed in a T cell tumor cell is not present in a normal T cell. If the target tumor antigen is present in a normal T cell, when the bispecific antigen-binding molecule is bound to an antigen that is the same as the target tumor antigen and is present in a normal T cell, the normal T cell is not substantially activated. When the bispecific antigen-binding molecule is bound to a normal T cell-side target antigen, the normal T cell is activated and the subtype of the normal T cell-side target antigen is present at a ratio that is sufficient for providing a sufficient number of activated T cell for the treatment of T cell tumor.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/13 - Immunoglobulins

Goods & Services

Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations

Goods & Services

Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations.

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations.

Abstract

A bispecific antibody including a first domain which specifically binds to a mutant calreticulin protein and a second domain which specifically binds to a CD3 antigen. A pharmaceutical composition including the bispecific antibody or a functional fragment thereof. A diagnostic method for a myeloproliferative neoplasm, including detecting a polypeptide in a biological sample with the bispecific antibody.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Goods & Services

Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations

Goods & Services

Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations.

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations.

Abstract

A process for preparing a diazabicyclooctane compound represented by the following formula (I): 1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07F 7/08 - Compounds having one or more C—Si linkages

Goods & Services

Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations

Goods & Services

Pharmaceutical preparations, namely, anti-infective preparations and substances for medical purposes; pharmaceutical preparations, namely, anti-infection preparations, antimicrobial preparations for treating bacterial infections, antifungal preparations

Abstract

The purpose of the present invention is to provide a medicine exhibiting a satisfactory anti-cancer effect by combining an antibody capable of binding to a mutant CALR protein with another anti-cancer agent.　Provided is a medicine for preventing and/or treating cancer, the medicine comprising a combination of (A) an antibody capable of binding specifically to a mutant calreticulin protein or a functional fragment thereof and (B) at least one drug selected from an alkylating agent, a platinum preparation, an antimetabolite, a ribonucleotide reductase inhibitor, a nucleotide analogue, a topoisomerase inhibitor, a microtubule assembly inhibiting drug, an anti-tumor antibiotic, an interferon, a cytokine preparation, a molecule targeting drug, a nucleic acid synthesis inhibitor, a JAK inhibitor and an immuno-oncology drug.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 38/21 - Interferons
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/46 - Hybrid immunoglobulins
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

A novel use of agonist to PD-1 is developed. Provided is a pharmaceutical composition for treating or preventing Th2-mediated diseases, the composition comprising an effective amount of a PD-1 agonist.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 37/08 - Antiallergic agents

Abstract

A method for producing a compound represented by formula (1) or a salt thereof, the method comprising: a step B for producing a compound represented by formula (3) [in formula (3), Boc represents a tert-butoxycarbonyl group] or a salt thereof by using a compound represented by formula (2) [in formula (2), Rarepresents a hydrogen atom or an optionally substituted arylmethyl group, Rbrepresents an optionally substituted alkyl group or a cyclic alkyl group, R3represents a hydrogen atom, a halogen atom, or a thiazol-2-yl group, and Xa represents a hydrogen atom or a halogen atom] or a salt thereof; and a step C for producing the compound represented by formula (1) or a salt thereof by using the compound represented by formula (3) or a salt thereof.

IPC Classes  ?

• C07D 487/08 - Bridged systems
• C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention pertains to a search for conditions necessary for an antibody against human PD-1 to possess an agonist activity, establishing of an agonist antibody optimized on the basis of such necessary conditions, and application of said agonist antibody as a drug for human inflammatory diseases. An agonist antibody against human PD-1 or a functional fragment thereof according to the present invention is characterized in that the antibody or the functional fragment thereof binds to domain #7, of human PD-1, represented by SEQ ID: 9.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 Å in the powder X-ray diffraction pattern.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A control agent comprising, as an active ingredient, a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl)oxyquinoline, azoxystrobin, picoxystrobin, pyraclostrobin, kresoxim-methyl, trifloxystrobin, metominostrobin, orysastrobin, famoxadone, fluoxastrobin, pyribencarb, cyazofamid, amisulbrom, flutolanil, mepronil, isofetamid, fluopyram, carboxin, thifluzamide, fluxapyroxad, furametpyr, penflufen, penthiopyrad, boscalid, diflumetorim, fluazinam, ferimzone, fenpyroximate, or an acid addition salt of any of these compounds shows an excellent controlling effect on Mesostigmata mites.

IPC Classes  ?

• A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
• A01P 7/04 - Insecticides

Abstract

A diagnostic, preventive, or therapeutic agent may be used for a myeloproliferative neoplasm. An antibody or a functional fragment thereof that binds to a cleaved mutant CALR protein, may include an antigen-recognition site in (a) a polypeptide chain having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a polypeptide chain having an amino acid sequence having deletion, substitution, or addition of one to several amino acids in SEQ ID NO: 1; and a diagnostic, preventive, or therapeutic agent for a myeloproliferative neoplasm containing the antibody.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided are: a higher-performance bispecific antibody that specifically binds to a mutant calreticulin protein; and a pharmaceutical composition that contains said antibody.　Provided is a bispecific antibody having: a first domain that specifically binds to a mutant calreticulin protein; and a second domain that specifically binds to a CD3 antigen.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins
• C12N 15/13 - Immunoglobulins
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/531 - Production of immunochemical test materials

Abstract

A Mesostigmata mite control composition comprising, as active ingredients: a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl)oxyquinoline; and at least one of other pest control agents exhibits an excellent control effect on Mesostigmata mites.

IPC Classes  ?

• A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
• A01N 25/04 - Dispersions or gels
• A01N 25/06 - Aerosols
• A01N 25/14 - Powders or granules wettable
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 47/22 - O-Aryl or S-Aryl esters thereof
• A01N 53/00 - Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
• A01N 57/12 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing acyclic or cycloaliphatic radicals
• A01N 57/14 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing aromatic radicals
• A01P 7/02 - Acaricides

Abstract

According to the present invention, the expression of a target protein is promoted in mammalian cells by co-introducing a polynucleotide containing an expression cassette of the target protein, a polynucleotide containing IR/MAR and a polynucleotide promoting the expression of the target protein, each as a separate polynucleotide, into the mammalian cells.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12P 21/00 - Preparation of peptides or proteins

Abstract

A process for preparing a diazabicyclooctane compound represented by the following formula (I): 1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

In the present invention, novel uses for PD-1 agonists have been developed. Provided is a pharmaceutical composition for treating or preventing Th2-mediated diseases, the composition containing an effective amount of a PD-1 agonist.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 37/08 - Antiallergic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Provided are: a novel compound, and a pharmaceutically acceptable salt thereof, represented by formula (1), the compound having a histamine H4 receptor-regulating effect and being useful in the treatment and/or prevention of an illness or state in which histamine H4 receptor participates; the use of the same; and a medical composition containing the same.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 11/06 - Antiasthmatics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 475/08 - Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. 2—; and Z represents a hydrogen atom or a hydroxyl group.]

IPC Classes  ?

• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61P 17/04 - Antipruritics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

A composition for lysing at least one type of staphylococcus bacteria selected from the group consisting of Staphylococcus hyicus, Staphylococcus chromogenes, Staphylococcus simulans, Staphylococcus schleiferi, and Staphylococcus felis, or for the prevention or treatment of diseases caused by said bacteria, said composition containing, as active ingredients: at least one bacteriophage selected from the group consisting of bacteriophages identified by accession number NITE BP-693 and bacteriophages identified by accession number NITE BP-694; and an endolysin, which is a protein specified by an amino acid sequence of SEQ ID NO: 1.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents
• A61P 27/16 - Otologicals
• A61P 31/04 - Antibacterial agents
• C07K 14/01 - DNA viruses

Abstract

The present invention relates to: a homogeneous composition which comprises a steroid compound and olopatadine and in which the steroid compound and olopatadine are present stably in a suspended state and in a dissolved state, respectively; and a method for producing the composition.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 9/10 - DispersionsEmulsions
• A61K 9/12 - AerosolsFoams
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 37/08 - Antiallergic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided are crystals of 1-((2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-(thiazol-2-yl)benzo[d]oxazol-4-yl)oxy)-1,1-difluoro-2-methylpropan-2-ol represented by formula (1),

IPC Classes  ?

• C07D 487/08 - Bridged systems

Abstract

This composition for lysis of Staphylococcus aureus or this composition for prevention or therapy of diseases caused by Staphylococcus aureus contains as active ingredients: at least one bacteriophage selected from the group consisting of the bacteriophage identified by Accession No. NITE BP-693 and the bacteriophage identified by Accession No. NITE BP-694; and an endolysin that is at least one protein selected from the group consisting of (a) a protein having the amino acid sequence of SEQ ID NO: 1; (b) proteins having an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 1; and (c) proteins having an amino acid sequence obtained by providing one or more amino acid substitutions, deletions, additions, and/or insertions to the amino acid sequence of SEQ ID NO: 1.

IPC Classes  ?

• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/00 - Drugs for disorders of the senses
• A61P 27/02 - Ophthalmic agents
• A61P 31/04 - Antibacterial agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 17/00 - Drugs for dermatological disorders
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 38/46 - Hydrolases (3)

Abstract

This composition is for lysing Staphylococcus aureus or treating or preventing diseases caused by Staphylococcus aureus, and contains, as active ingredients, at least one bacteriophage selected from the group consisting of the bacteriophage specified by Deposit No. NITE BP-693 and the bacteriophage specified by Deposit No. NITE BP-694, and an endolysin, which is at least one protein selected from the group consisting of (a) a protein having the amino acid sequence described in SEQ ID NO: 1, (b) proteins having amino acid sequences having at least 80% identity with the amino acid sequence described in SEQ ID NO: 1, and (c) proteins having amino acid sequences obtained by providing at least one amino acid substitution, deletion, addition, and/or insertion to the amino acid sequence described in SEQ ID NO: 1.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/46 - Hydrolases (3)
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/00 - Drugs for disorders of the senses
• A61P 27/02 - Ophthalmic agents
• A61P 31/04 - Antibacterial agents
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A composition for lysing Staphylococcus aureus or a composition for preventing or treating a disease caused by Staphylococcus aureus, said composition comprising, as active ingredients, at least one bacteriophage selected from the group consisting of a bacteriophage identified under accession number NITE BP-693 and a bacteriophage identified under accession number NITE BP-694, and an endolysin that is at least one protein selected from the group consisting of (a) a protein having the amino acid sequence represented by SEQ ID NO: 1, (b) a protein that has an amino acid sequence having at least 80% identity to the amino acid sequence represented by SEQ ID NO: 1, and (c) a protein that has an amino acid sequence with the substitution, deletion, addition and/or insertion of one or more amino acids in the amino acid sequence represented by SEQ ID NO: 1.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/46 - Hydrolases (3)
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/00 - Drugs for disorders of the senses
• A61P 27/02 - Ophthalmic agents
• A61P 31/04 - Antibacterial agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

Provided is a compound represented by the following formula (1) and a pharmacologically acceptable salt, which have a regulatory activity for a histamine H4 receptor and are useful for the treatment and/or prevention of diseases or conditions in which the histamine H4 receptor is involved; use of the same; and a pharmaceutical composition comprising the same.

IPC Classes  ?

• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 471/08 - Bridged systems
• C07D 487/04 - Ortho-condensed systems
• C07D 487/08 - Bridged systems
• C07D 487/10 - Spiro-condensed systems
• C07D 251/70 - Other substituted melamines
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

Goods & Services

Cookies and crackers

Abstract

An agent for controlling scald disease, said agent comprising as an active ingredient a lactic acid bacterium that has an ability to control scald disease.

IPC Classes  ?

• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• A01P 3/00 - Fungicides

Abstract

The purpose of the present invention is to provide a novel agent for suppressing bitterness in asenapine. According to the present invention, there is provided an agent for suppressing bitterness in asenapine, the agent including, as an active ingredient, at least one selected from the group consisting of polyols (other than aromatic polyols), aliphatic hydroxy acids, saccharine, acesulfame potassium, alkyl sulfate, povidone, magnesium stearate, talc, and sodium stearyl fumarate. This agent for suppressing bitterness can be used when administering an asenapine-containing composition, the asenapine-containing composition preferably being a sublingual orally disintegrating tablet, and more preferably being a lyophilized sublingual orally disintegrating tablet.

IPC Classes  ?

• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 9/06 - OintmentsBases therefor
• A61K 9/12 - AerosolsFoams
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

Provided is a solid formulation for rice pest control, which is a coated granule or extruded granule and comprises at least one effective component selected from the group consisting of flupyrimin as represented by formula (1): and salts thereof, and also a solid carrier, a surfactant, and a binder.

IPC Classes  ?

• A01N 25/12 - Powders or granules
• A01N 25/26 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01P 7/04 - Insecticides
• A01P 17/00 - Pest repellants

Abstract

This plant parasitic nematode controlling agent for Tylenchoidea contains, as an active ingredient, at least one compound selected from the group consisting of the compound represented by formula (1), the compound represented by formula (2), the compound represented by formula (3), an enantiomer thereof, and an agriculturally and horticulturally acceptable acid addition salt thereof.

IPC Classes  ?

• A01N 25/12 - Powders or granules
• A01N 25/14 - Powders or granules wettable
• A01P 5/00 - Nematocides
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system

Abstract

Provided is a diagnostic, prophylactic or therapeutic drug for myeloproliferative neoplasms.　An antibody which can bind to a truncated mutant CALR protein and has an antigen-recognition site in (a) a polypeptide chain comprising the amino acid sequence represented by SEQ ID NO: 1 or (b) a polypeptide chain comprising such an amino acid sequence that one amino acid residue or several amino acid residues are deleted, substituted or added in SEQ ID NO: 1, or a functional fragment of the antibody; and a diagnostic, prophylactic or therapeutic drug for myeloproliferative neoplasms, which comprises the antibody.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations for the treatment of osteoarthritis and joint disease; prepackaged injectable medicines; prepackaged injectable sodium hyaluronate solutions for medical use; pre-filled syringes for medical purposes; pre-filled syringes containing sodium hyaluronate solutions for the treatment of osteoarthritis and joint disease. Medical apparatus and instruments; syringes for injections; injection devices for pharmaceuticals; injectors for medical purposes; medical apparatus, namely, self-contained syringes for injecting prepackaged injectable medicine, medical self-contained syringes for injecting prepackaged injectable sodium hyaluronate solutions.

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations for the treatment of osteoarthritis and joint disease; prepackaged injectable medicines; prepackaged injectable sodium hyaluronate solutions for medical use; pre-filled syringes for medical purposes; pre-filled syringes containing sodium hyaluronate solutions for the treatment of osteoarthritis and joint disease. Medical apparatus and instruments; syringes for injections; injection devices for pharmaceuticals; injectors for medical purposes; medical apparatus, namely, self-contained syringes for injecting prepackaged injectable medicine, medical self-contained syringes for injecting prepackaged injectable sodium hyaluronate solutions.

Abstract

A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 Å in the powder X-ray diffraction pattern.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.

IPC Classes  ?

• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• C07H 15/224 - Cyclohexane rings, substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexane rings, e.g. destomycin, fortimicin, neamine
• A61P 31/04 - Antibacterial agents

Abstract

122 represents a C1-6 alkyl group substituted with a halogen).

IPC Classes  ?

• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 25/04 - Dispersions or gels
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01P 7/04 - Insecticides

Abstract

The present invention provides a plant disease control agent which contains a compound represented by formula (1). (In the formula, each of X1and X4represents a fluorine atom, a chlorine atom or the like; each of X2and X3represents a hydrogen atom or the like; Xa represents a group expressed by formula (2) or (3); each of Ja and Jb represents an oxygen atom or the like; G represents an optionally substituted phenyl group or the like; Aa represents an optionally substituted alkyl group, a phenyl group or the like; Q represents an oxygen atom or the like; and Ab represents a heterocyclic group which may be substituted by a halogen atom or the like.)

IPC Classes  ?

• C07D 213/79 - AcidsEsters
• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• A01N 47/20 - N-Aryl derivatives thereof
• A01P 3/00 - Fungicides
• C07D 213/81 - AmidesImides
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A composition for controlling mesostigmata mites exhibits an excellent control effect on mesostigmata mites, the composition including as active ingredients: a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl) oxyquinoline; and at least one other pest control agent.

IPC Classes  ?

• A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A01N 47/06 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom containing —O—CO—O— groupsThio-analogues thereof
• A01N 47/22 - O-Aryl or S-Aryl esters thereof
• A01N 53/04 - Esters containing the group , wherein the carbon atom marked with an asterisk is acyclic or part of a ring or ring systemThio-analogues thereof having heterocyclic rings
• A01N 53/08 - Esters containing the group , wherein the carbon atom marked with an asterisk is acyclic or part of a ring or ring systemThio-analogues thereof the carbon atom marked with an asterisk being acyclic and directly bound to a carbon atom of a six-membered aromatic ring, e.g. benzyl estersThio-analogues thereof with aryloxy groups bound to the six-membered aromatic ring, e.g. phenoxybenzyl estersThio-analogues thereof
• A01N 57/14 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing aromatic radicals
• A01N 57/20 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds containing acyclic or cycloaliphatic radicals
• A01P 7/02 - Acaricides

Abstract

Provided are a plant disease control agent and a plant disease control method, the plant disease control agent containing a compound represented by formula (1) as an active ingredient. (In the formula, X1and X4each independently represent a fluorine atom or the like, X2and X3 each independently represent a hydrogen atom or a fluorine atom, Xa is a group represented by formula (2), (3), (4), (5) or (6), J represents an oxygen atom or the like, Q represents an oxygen atom or the like, A represents a phenyl group or the like which may have a substituent, Aa represents a piperidin-1-yl group or the like, Qb represents an oxygen atom or the like, Ab represents a hydrogen atom or the like, Z represents a hydrogen atom or the like, m represents an integer of 1-3, Ja and Jb each independently represent an oxygen atom or the like, G represents a phenyl group or the like, and Ad represents an alkyl group, an alkyloxy group, or the like.)

IPC Classes  ?

• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 43/52 - 1,3-DiazolesHydrogenated 1,3-diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A01N 43/54 - 1,3-DiazinesHydrogenated 1,3-diazines
• A01N 43/58 - 1,2-DiazinesHydrogenated 1,2-diazines
• A01N 43/60 - 1,4-DiazinesHydrogenated 1,4-diazines
• A01N 43/653 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• A01N 43/76 - 1,3-OxazolesHydrogenated 1,3-oxazoles
• A01N 43/78 - 1,3-ThiazolesHydrogenated 1,3-thiazoles
• A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• A01N 43/84 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms six-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,4
• A01N 43/86 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms six-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
• A01N 47/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
• A01N 47/12 - Carbamic acid derivatives, i.e. containing the group —O—CO—NThio-analogues thereof containing a —O—CO—N group, or a thio-analogue thereof, neither directly attached to a ring nor the nitrogen atom being a member of a heterocyclic ring
• A01P 3/00 - Fungicides

Abstract

A process for preparing a diazabicyclooctane compound represented by the following formula (I): 1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

Staphylococcus hyicusStaphylococcus chromogenesStaphylococcus chromogenes and the like. This finding enables the provision of: a composition for lysing these staphylococcal bacteria; a composition for treating or preventing diseases associated with these staphylococcal bacteria; and others.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 17/00 - Drugs for dermatological disorders
• A61P 31/04 - Antibacterial agents

Abstract

Provided is a compound represented by general formula (1), or a pharmacologically acceptable salt thereof.

IPC Classes  ?

• C07D 487/08 - Bridged systems
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, wherein the therapeutic agent contains as an active ingredient a compound represented by general formula (1) and/or a pharmacologically acceptable salt thereof. [In formula (1), R1and R21-61-6 alkyl group, etc.; R3represents a hydrogen atom; R4222222222-; and Z represents a hydrogen atom or a hydroxyl group.]

IPC Classes  ?

• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a crystal of 1-((2-(3, 6-diazabicyclo[3.1.1]heptane-3-yl)-7-(thiazole-2-yl)benzo[d]oxazole-4-yl)oxy)-1,1-difluoro-2-methylpropane-2-ol represented by formula (1).

IPC Classes  ?

• C07D 487/08 - Bridged systems
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• A61P 17/06 - Antipsoriatics
• A61P 17/10 - Anti-acne agents
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators
• A61P 37/08 - Antiallergic agents

Abstract

The present invention discloses a water-dispersible agrochemical composition which is in a solid state at 30°C, and which contains: an agrochemically active ingredient (A) that is a compound represented by formula (I) or an agriculturally and horticulturally acceptable acid addition salt thereof; one or more additives; and one or more surfactants. This water-dispersible agrochemical composition has excellent storage stability and excellent physical properties for preparations.

IPC Classes  ?

• A01N 47/06 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom containing —O—CO—O— groupsThio-analogues thereof
• A01N 25/14 - Powders or granules wettable
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01N 47/24 - Carbamic acid derivatives, i.e. containing the group —O—CO—NThio-analogues thereof containing the groups , or Thio-analogues thereof
• A01N 47/44 - GuanidineDerivatives thereof
• A01N 51/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds having the sequences of atoms O—N—S, X—O—S, N—N—S, O—N—N or O-halogen, regardless of the number of bonds each atom has and with no atom of these sequences forming part of a heterocyclic ring
• A01N 57/16 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing heterocyclic radicals
• A01P 3/00 - Fungicides
• A01P 7/04 - Insecticides

Abstract

Disclosed are: a method for manufacturing a compound (5-epi-4"-N-(L-isoceryl)apramycin) and 5-epiapramycin; and an intermediate used for said method. The method of the present invention is useful in that the compound (5-epi-4"-N-(L-isoceryl)apramycin) can be efficiently and completely produced.

IPC Classes  ?

• C07H 15/224 - Cyclohexane rings, substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexane rings, e.g. destomycin, fortimicin, neamine
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 31/04 - Antibacterial agents

Abstract

A compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof: 2—; and Z represents a hydrogen atom or a hydroxyl group].

IPC Classes  ?

• C07D 498/08 - Bridged systems
• C07D 451/14 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantaneCyclic acetals thereof
• C07D 487/08 - Bridged systems

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations for the treatment of osteoarthritis and joint disease; prepackaged injectable medicine; prepackaged injectable sodium hyaluronate solutions; pre-filled syringes for medical purposes. Injectors for medical purposes; medical apparatus, including self-contained syringes for injecting prepackaged injectable medicine; medical apparatus, including self-contained syringes for injecting prepackaged injectable sodium hyaluronate solutions.

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations for the treatment of osteoarthritis and joint disease; prepackaged injectable medicine; prepackaged injectable sodium hyaluronate solutions; pre-filled syringes for medical purposes. Injectors for medical purposes; medical apparatus, including self-contained syringes for injecting prepackaged injectable medicine; medical apparatus, including self-contained syringes for injecting prepackaged injectable sodium hyaluronate solutions.

Goods & Services

(1) Antibiotics;

Abstract

This liquid agent for external use for prevention and treatment of onychomycosis contains a drug with anti-onychomycotic activity, a volatile alcohol, and a delivery enhancer.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 9/08 - Solutions
• A61K 31/415 - 1,2-Diazoles
• A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 17/00 - Drugs for dermatological disorders
• A61P 31/10 - Antimycotics

Abstract

This liquid agent for external use for prevention and treatment of onychomycosis contains a drug with anti-onychomycotic activity, a volatile alcohol, and a delivery enhancer.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/415 - 1,2-Diazoles
• A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 17/00 - Drugs for dermatological disorders
• A61P 31/10 - Antimycotics

Abstract

A process for producing crystals of a compound represented by the following formula (I): by crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, such as sodium chloride. Such crystals can be subjected to lyophilization to provide a lyophilized composition having a desirable storage stability.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 47/02 - Inorganic compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

[Problem] To provide a method for producing and isolating a target quinolone derivative using general industrial facilities with high purity. [Solution] The present invention provides a method for producing a quinolone derivative, the method comprising performing a reaction between a ketone and an anthranilic acid derivative using an aluminium halide and removing the aluminium halide under a basic condition.

IPC Classes  ?

• C07D 215/233 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4

Abstract

When the sealedness of a luer nozzle is breached at the same time as that of a luer lock portion during capping or uncapping, uncapping becomes less easy and leakage of drug solution inside the syringe increases. A tip cap 10 includes: a thick disk-like base portion 11 which has a top face 15 on one side; a cylindrical inner tube portion 13 which is protrudingly formed from the other side opposite (in the thickness direction) the top face 15 of the base portion 11 and is for coveringly sealing, with at least an inner circumferential surface thereof, a luer nozzle; and a cylindrical outer tube portion 14 which is protrudingly and surroundingly formed coaxial with the inner tube portion from the other side opposite (in the thickness direction) the top face 15 of the base portion 11 and which is for coveringly sealing a luer lock. The outer tube portion 14 has an inner circumferential surface 141 that covers the luer lock and an outer circumferential surface that is connected to an outer circumferential surface of the base portion 11 to form an outer circumferential surface 17 of the cap. The cap has, formed on the outer circumferential surface at a location closer to the top face than the base of the outer tube portion, an annular groove 18 that extends in a circumferential direction.

IPC Classes  ?

• A61M 5/31 - Syringes Details
• A61M 5/28 - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle

Abstract

To provide an optical probe that can be miniaturized with ease and that changes the direction of light emitted from a light source and guided by an optical fiber to a direction of side illumination using a very simple method so that irradiation is made more efficient and heat generation is reduced, the optical probe 11 is provided with: a substantially cylindrical probe distal end 13 that has a substantially cylindrical first light transmissive region 22 and a second light transmissive region 23 that covers an outer surface of the first light transmissive region 22; and an optical fiber 12 that optically connects the light source to the probe distal end 13; wherein when light emitted from the core 2 of the optical fiber 12 enters the first light transmissive region 22, the optical probe 11 satisfies the relationship n1

IPC Classes  ?

• A61B 18/22 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor

Abstract

A process for producing a compound of the following Formula (VII-CR): The process involving providing a compound represented by the following Formula (VI): 1-6 alkyl or a heterocycle.

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• C07D 471/08 - Bridged systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for producing methyl dichlorophosphane, said method comprising a step for reacting methane with phosphorus trichloride in the presence of an additive with the use of a metal compound and/or a metal compound held on a support.

IPC Classes  ?

• C07F 9/52 - Halophosphines
• B01J 23/04 - Alkali metals
• B01J 23/755 - Nickel
• B01J 27/08 - Halides
• B01J 27/128 - HalogensCompounds thereof with iron group metals or platinum group metals
• B01J 27/138 - HalogensCompounds thereof with alkaline earth metals, magnesium, beryllium, zinc, cadmium or mercury
• C07B 61/00 - Other general methods

Abstract

A compound represented by the formula, which has an RORγt inhibiting effect and is useful as a prophylactic or therapeutic agent for autoimmune diseases, allergic diseases, etc., or a salt thereof.

IPC Classes  ?

• C07D 233/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4245 - Oxadiazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• A61P 11/14 - Antitussive agents
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/06 - Antipsoriatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators
• A61P 37/08 - Antiallergic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 451/02 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof

Abstract

Acremonium cellulolyticus, and various primers were designed based on the information. PCR was carried out using the various primers thus designed and genomic DNA or cDNA as a template. As a result, gene fragments of endoglucanases and β-glucosidases were obtained. Primers were designed based on the gene fragments, and PCR was carried out to amplify nine genes of endoglucanases and β-glucosidases. The nucleotide sequences thereof were sequenced, and the present invention was completed.

IPC Classes  ?

• C12N 9/42 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4-glucosidic bonds, e.g. cellulase
• C12P 19/02 - Monosaccharides
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
• D06M 16/00 - Biochemical treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, e.g. enzymatic
• D21C 5/00 - Other processes for obtaining cellulose, e.g. cooking cotton linters
• D21C 5/02 - Working-up waste paper
• D21H 21/10 - Retention agents or drainage improvers
• A23K 20/189 - Enzymes
• A23K 10/14 - Pretreatment of feeding-stuffs with enzymes

Abstract

Provided is a compound represented by the formula, or a salt thereof, the compound having RORγt-inhibiting activity and being useful as a prophylactic or therapeutic agent for autoimmune or allergic diseases.

IPC Classes  ?

• C07D 231/56 - BenzopyrazolesHydrogenated benzopyrazoles
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/06 - Antipsoriatics
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Provided is an aqueous formulation containing: ustekinumab; at least one selected from histidine and a salt thereof; and water. The content of histidine and/or a salt thereof is 50 to 90 mM in terms of histidine.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 9/08 - Solutions
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 17/06 - Antipsoriatics
• A61P 37/02 - Immunomodulators

Abstract

A plant disease control agent which contains a compound represented by formula (1) as an active ingredient.

IPC Classes  ?

• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 43/52 - 1,3-DiazolesHydrogenated 1,3-diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A01N 43/54 - 1,3-DiazinesHydrogenated 1,3-diazines
• A01N 43/56 - 1,2-DiazolesHydrogenated 1,2-diazoles
• A01N 43/58 - 1,2-DiazinesHydrogenated 1,2-diazines
• A01N 43/60 - 1,4-DiazinesHydrogenated 1,4-diazines
• A01N 43/653 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• A01N 43/78 - 1,3-ThiazolesHydrogenated 1,3-thiazoles
• A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• A01N 43/84 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms six-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,4
• A01P 3/00 - Fungicides
• C07D 213/30 - Oxygen atoms
• C07D 213/81 - AmidesImides
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A control agent exhibiting an excellent control effect on Mesostigmata mites and having as effective components thereof: a specific quinoline derivative compound such as 8–fluoro–2, 3–dimethyl–6–(1,1–dimethylethyl)–4–(methylcarbonyl) oxyquinoline; azoxystrobin; picoxystrobin; pyraclostrobin; kersoxim methyl; trifloxystrobin; metominostrobin; olisastrobin; famoxadone; fluoxastrobin; pyribencarb; cyazofamid; amisulbrom; flutolanil; mepronil; isofetamid; fluopyram; carboxin; thifluzamide; fluxapyroxad; furametpyr; penflufen; penthiopyrad; boscalid; diflumetorim; fluazinam; ferimzone; fenpyroximate; or an acid addition salt of these compounds.

IPC Classes  ?

• A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
• A01N 47/06 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom containing —O—CO—O— groupsThio-analogues thereof
• A01P 7/02 - Acaricides

Abstract

A process for preparing a diazabicyclooctane compound represented by the following formula (I): 1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

IPC Classes  ?

• C07D 211/06 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
• C07D 295/00 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
• C07D 471/08 - Bridged systems
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.

IPC Classes  ?

• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• C07H 15/224 - Cyclohexane rings, substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexane rings, e.g. destomycin, fortimicin, neamine
• A61P 31/04 - Antibacterial agents

Abstract

Disclosed are: a compound represented by general formula (I), a pharmaceutically acceptable salt thereof or a solvate of the same; a medicinal composition comprising the same; use of the same for preventing or treating infectious diseases; and a method for preventing or treating infectious diseases, said method comprising using the same. The compound represented by general formula (I), which has an antibacterial activity against both of gram-positive bacteria and gram-negative bacteria, is useful for preventing or treating infectious diseases caused by these bacteria.

IPC Classes  ?

• C07H 5/06 - Aminosugars
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 17/00 - Drugs for dermatological disorders
• A61P 27/02 - Ophthalmic agents
• A61P 27/16 - Otologicals
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/04 - Antibacterial agents

Abstract

Provided is a compound represented by general formula (1) or a pharmaceutically-acceptable salt thereof. [In formula (1), R1 and R2 may be the same or different from each other, and each represents a hydrogen atom, a halogen atom, a hydroxy group, a carboxy group, a cyano group, or an optionally-substituted C1-6 alkyl group or the like; R3 represents a hydrogen atom; R4 represents an optionally-substituted 4- to 10-membered monocyclic heterocyclic group containing 1-4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxy group.]

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 11/06 - Antiasthmatics
• A61P 17/06 - Antipsoriatics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• C07D 487/08 - Bridged systems
• C07D 498/08 - Bridged systems

Abstract

Provided is a compound or a salt thereof, represented by the formula shown, which has a RORγt inhibitory effect and is useful as a preventive or therapeutic agent for autoimmune diseases, allergies, and the like.

IPC Classes  ?

• C07D 231/20 - One oxygen atom attached in position 3 or 5
• A61K 31/415 - 1,2-Diazoles
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/06 - Antiasthmatics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 27/02 - Ophthalmic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4′-epi-feudomycin, which are typical impurities possibly contained in 4′-epi-daunorubicin as a starting material, by using an organic acid salt of 4′-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.

IPC Classes  ?

• C07B 63/02 - PurificationSeparation specially adapted for the purpose of recovering organic compoundsStabilisationUse of additives by treatment giving rise to a chemical modification
• C07C 49/423 - Saturated compounds containing a keto group being part of a ring polycyclic a keto group being part of a condensed ring system
• C07H 15/252 - Naphthacene radicals, e.g. daunomycins, adriamycins
• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine

Abstract

Provided is a method for producing a compound represented by formula (I), wherein a compound represented by formula (A) is used as a starting material, and an intermediate represented by formula (B) is produced using a trifluoroacetic acid ester and a metal base.

IPC Classes  ?

• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates